Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 8 | 2012 | 5223 | 0.440 |
Why?
|
| Thionucleotides | 1 | 2009 | 107 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2009 | 203 | 0.330 |
Why?
|
| Lung Neoplasms | 9 | 2018 | 13104 | 0.320 |
Why?
|
| Taxoids | 3 | 2009 | 666 | 0.320 |
Why?
|
| Neoplasms, Unknown Primary | 3 | 2014 | 104 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2013 | 11525 | 0.270 |
Why?
|
| Paclitaxel | 3 | 2009 | 1708 | 0.210 |
Why?
|
| Esophageal Neoplasms | 4 | 2013 | 1585 | 0.190 |
Why?
|
| Antineoplastic Agents | 5 | 2012 | 13693 | 0.170 |
Why?
|
| Immunotoxins | 2 | 1998 | 179 | 0.160 |
Why?
|
| Bone Neoplasms | 2 | 2022 | 2530 | 0.160 |
Why?
|
| Deoxycytidine | 3 | 2008 | 826 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 624 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1995 | 1381 | 0.150 |
Why?
|
| Carboplatin | 2 | 2009 | 801 | 0.140 |
Why?
|
| Tracheal Neoplasms | 1 | 1996 | 124 | 0.130 |
Why?
|
| Vascular Neoplasms | 1 | 1997 | 175 | 0.130 |
Why?
|
| Vena Cava, Inferior | 1 | 1997 | 440 | 0.110 |
Why?
|
| Lymphoma | 2 | 1999 | 1877 | 0.110 |
Why?
|
| Stomach Neoplasms | 3 | 2013 | 1332 | 0.110 |
Why?
|
| Cholestasis | 1 | 1995 | 378 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2018 | 1094 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 3 | 2009 | 892 | 0.100 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1997 | 501 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 148 | 0.100 |
Why?
|
| Sarcoma | 1 | 2022 | 1897 | 0.090 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 806 | 0.090 |
Why?
|
| Consensus | 1 | 2018 | 2960 | 0.090 |
Why?
|
| Ricin | 2 | 1998 | 72 | 0.070 |
Why?
|
| Pyridines | 2 | 2022 | 2825 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1996 | 1378 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 1660 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 2 | 2013 | 2727 | 0.060 |
Why?
|
| Aged | 16 | 2013 | 163288 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2006 | 965 | 0.050 |
Why?
|
| DNA Repair | 1 | 2011 | 2046 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2012 | 1972 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 9274 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2001 | 380 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 1999 | 8642 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 2917 | 0.050 |
Why?
|
| Pyrazines | 1 | 2006 | 1230 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 4933 | 0.050 |
Why?
|
| Middle Aged | 15 | 2013 | 213390 | 0.050 |
Why?
|
| Aged, 80 and over | 7 | 2012 | 57776 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2011 | 2267 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2001 | 2274 | 0.040 |
Why?
|
| Anilides | 1 | 2022 | 408 | 0.040 |
Why?
|
| Adenocarcinoma | 3 | 2011 | 6364 | 0.040 |
Why?
|
| Adult | 14 | 2013 | 214052 | 0.040 |
Why?
|
| Humans | 27 | 2022 | 744366 | 0.040 |
Why?
|
| Cisplatin | 3 | 2013 | 1662 | 0.040 |
Why?
|
| Male | 18 | 2013 | 350115 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2012 | 11031 | 0.040 |
Why?
|
| Camptothecin | 2 | 2013 | 576 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2001 | 1655 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 9955 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2011 | 6366 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2011 | 7282 | 0.040 |
Why?
|
| Genotype | 1 | 2011 | 12952 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2011 | 602 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 5856 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2022 | 4851 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 5534 | 0.030 |
Why?
|
| Antigens, CD19 | 1 | 1998 | 380 | 0.030 |
Why?
|
| Female | 16 | 2013 | 380193 | 0.030 |
Why?
|
| Treatment Outcome | 7 | 2011 | 63107 | 0.030 |
Why?
|
| Laparotomy | 1 | 1997 | 473 | 0.030 |
Why?
|
| Vincristine | 1 | 1996 | 1039 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 1995 | 247 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2013 | 2251 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1997 | 640 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 1997 | 1641 | 0.020 |
Why?
|
| Prednisone | 1 | 1996 | 1574 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2012 | 170 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2013 | 313 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 1996 | 862 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1996 | 2242 | 0.020 |
Why?
|
| Recurrence | 2 | 1999 | 8340 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 1995 | 1000 | 0.020 |
Why?
|
| Neoplasms | 3 | 2006 | 21696 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 411 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2011 | 440 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1996 | 2234 | 0.020 |
Why?
|
| Quality of Life | 2 | 2008 | 12802 | 0.020 |
Why?
|
| Orthopedic Procedures | 1 | 1999 | 1289 | 0.020 |
Why?
|
| Drainage | 1 | 1995 | 1142 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1996 | 1257 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1997 | 3616 | 0.020 |
Why?
|
| Dyspnea | 1 | 1996 | 1303 | 0.020 |
Why?
|
| Survival Rate | 1 | 2001 | 12788 | 0.020 |
Why?
|
| Fluorouracil | 2 | 2005 | 1619 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 1997 | 6896 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2011 | 783 | 0.020 |
Why?
|
| Age Factors | 1 | 2001 | 18373 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2011 | 7914 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 2924 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 10943 | 0.010 |
Why?
|
| Antibodies | 1 | 2011 | 2460 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2916 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6539 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1998 | 5181 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 1335 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2725 | 0.010 |
Why?
|
| Carcinoma | 1 | 2011 | 2375 | 0.010 |
Why?
|
| Time Factors | 1 | 2001 | 40075 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1995 | 4446 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2011 | 3743 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3707 | 0.010 |
Why?
|
| Mutation | 2 | 2014 | 29786 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 9445 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1999 | 39052 | 0.010 |
Why?
|
| Asthma | 1 | 1996 | 6010 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1999 | 40559 | 0.010 |
Why?
|
| Young Adult | 2 | 2013 | 56429 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 4034 | 0.010 |
Why?
|
| Pericardiectomy | 1 | 1995 | 45 | 0.010 |
Why?
|
| Cytarabine | 1 | 1997 | 692 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2011 | 7882 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 9647 | 0.010 |
Why?
|
| Adolescent | 2 | 1999 | 85779 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 1999 | 77460 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 20130 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 13882 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 29060 | 0.010 |
Why?
|
| Methotrexate | 1 | 1997 | 1728 | 0.010 |
Why?
|
| Folic Acid | 1 | 1997 | 1300 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2013 | 53290 | 0.000 |
Why?
|
| Reoperation | 1 | 1995 | 4201 | 0.000 |
Why?
|
| United States | 1 | 2011 | 69872 | 0.000 |
Why?
|
| DNA | 1 | 1997 | 7294 | 0.000 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1997 | 5172 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1995 | 12961 | 0.000 |
Why?
|
| Animals | 1 | 1997 | 168768 | 0.000 |
Why?
|
Concepts
(135)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(52)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_